NCT00746837View on ClinicalTrials.gov

AZD5672 Absolute Bioavailability Study

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Healthy Volunteers

Interventions

DRUG

AZD5672

single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period

DRUG

AZD5672

50 mg od, 12 days

DRUG

AZD5672

150mg od, 12 days

Trial Locations (1)

Unknown

Research Site, Harrow

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY